NexImmune, Inc.
NEXIOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$139
P/E Ratio—
52W High$1.01
52W Low$0.0001
NexImmune, Inc. (NEXI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NEXI · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 7, 2024EPS Actual
-$1.69
Revenue
—
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 7, 2024
After Market Close
✓ 2-Quarter EPS Beat Streak
NEXI reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$13.25 | — | — | — | — | — |
| ◌ Q3 FY2026 | Aug 14, 2026 | -$16.83 | — | — | — | — | — |
| ◌ Q3 FY2025 | Aug 11, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | May 29, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Mar 27, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Dec 26, 2024 | — | — | — | — | — | — |
| — Q3 FY2024 | Aug 7, 2024 | — | -$1.69 | — | — | — | — |
| ▲ Q2 FY2024 | Apr 16, 2024 | -$5.85 | -$4.99 | +14.7% | — | — | — |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$13.25
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$16.83
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 11, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 29, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 27, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Dec 26, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 7, 2024
EPS Actual
-$1.69
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Apr 16, 2024Beat
EPS Actual
-$4.99
EPS Est.
-$5.85
EPS Surpr.
+14.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Q3 FY2029 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q2 FY2029 | $-0.53 | $-0.53 | $-0.53 | 1 |
| Q1 FY2029 | $-0.80 | $-0.80 | $-0.80 | 1 |
| Q4 FY2028 | $-5.85 | $-5.85 | $-5.85 | 1 |
| Q3 FY2028 | $-5.87 | $-5.87 | $-5.87 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2024 | Aug 7, 2024 | — | $1.22 | $1.12 | -8.20% |
| ▲ Q2 FY2024 | Apr 16, 2024 | +14.7% | $3.55 | $3.47 | -2.25% |
| ▲ Q1 FY2024 | Feb 7, 2024 | +14.1% | $10.51 | $9.20 | -12.46% |
| ▼ Q4 FY2023 | Nov 17, 2023 | -25.3% | $2.49 | $2.48 | -0.40% |
| ▲ Q3 FY2023 | Aug 10, 2023 | +0.0% | $6.38 | $6.68 | +4.70% |
| ▲ Q2 FY2023 | May 15, 2023 | +17.8% | $7.00 | $7.00 | +0.00% |
Q3 FY2024-8.20%
Report Date
Aug 7, 2024
EPS Beat/Miss
—
Price Before
$1.22
Price After
$1.12
Q2 FY2024-2.25%
Report Date
Apr 16, 2024
EPS Beat/Miss
+14.7%
Price Before
$3.55
Price After
$3.47
Q1 FY2024-12.46%
Report Date
Feb 7, 2024
EPS Beat/Miss
+14.1%
Price Before
$10.51
Price After
$9.20
Q4 FY2023-0.40%
Report Date
Nov 17, 2023
EPS Beat/Miss
-25.3%
Price Before
$2.49
Price After
$2.48
Q3 FY2023+4.70%
Report Date
Aug 10, 2023
EPS Beat/Miss
+0.0%
Price Before
$6.38
Price After
$6.68
Q2 FY2023+0.00%
Report Date
May 15, 2023
EPS Beat/Miss
+17.8%
Price Before
$7.00
Price After
$7.00
Avg Beat Reaction-2.50%
Avg Miss Reaction-0.40%
Beat Rate4 / 6 quarters
Largest Move-12.46% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NEXI ends December
NexImmune, Inc. (NEXI) most recently reported earnings on August 7, 2024 for Q3 FY2024, posting EPS of $-1.69 (in line with the analyst consensus of —). NEXI has beaten EPS estimates for 2 consecutive quarters. The next NEXI earnings date is expected around September 1, 2026.
Each quarter, investors track NEXI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NEXI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NEXI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NEXI earnings · 4 questionsNexImmune, Inc.'s next earnings report is expected around September 1, 2026. NEXI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NEXI historically reports after market close (AMC).
NEXI earnings datewhen is NEXI earningsNEXI next earnings datewhen does NEXI report earningsNEXI earnings calendar
▸ Source: FMP · NexImmune, Inc. SEC filings · US GAAP · NexImmune, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026